Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(0.47)
# 3,862
Out of 4,829 analysts
228
Total ratings
n/a
Success rate
-4.08%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Overweight | $113 → $112 | $46.01 | +143.43% | 19 | May 7, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $23 | $18.61 | +23.59% | 7 | May 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $163 → $81 | $36.37 | +122.71% | 16 | May 7, 2025 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $2.32 | +201.72% | 16 | Apr 28, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $67 → $123 | $76.70 | +60.37% | 6 | Mar 27, 2025 | |
| XFOR X4 Pharmaceuticals | Reiterates: Overweight | $90 | $3.34 | +2,594.61% | 4 | Mar 26, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $7.11 | +321.94% | 5 | Mar 20, 2025 | |
| MREO Mereo BioPharma Group | Reiterates: Overweight | $7 | $2.50 | +180.00% | 10 | Mar 18, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $99 → $132 | $46.65 | +182.96% | 8 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | $25 | $7.75 | +222.58% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $20.45 | +22.25% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $36.09 | +226.96% | 18 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 | $32.15 | +11.98% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $20.18 | +232.01% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $6.22 | +237.89% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $8.11 | +257.58% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $2.85 | +496.49% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $0.80 | +901.38% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $13.15 | +341.06% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.63 | +318.25% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.60 | +221.43% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $2.05 | +582.93% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.32 | +884.85% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.68 | - | 3 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.55 | +1,254.84% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $0.48 | +1,151.56% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.59 | +1,157.86% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $2.80 | +721.43% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.13 | +79,546.02% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.67 | +5,989.41% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $2.79 | +14,236.92% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.79 | +10,640.46% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,500 | $0.32 | +1,100,528.93% | 1 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.65 | +2,606.77% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.23 | +3,558.54% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $0.70 | +1,471.43% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.14 | +5,163.16% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.13 | +7,864.60% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.28 | +196,775.00% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.54 | +29,789.78% | 1 | Jan 9, 2020 |
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $113 → $112
Current: $46.01
Upside: +143.43%
Rigel Pharmaceuticals
May 7, 2025
Maintains: Neutral
Price Target: $20 → $23
Current: $18.61
Upside: +23.59%
Sarepta Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $36.37
Upside: +122.71%
Taysha Gene Therapies
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.32
Upside: +201.72%
Soleno Therapeutics
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $76.70
Upside: +60.37%
X4 Pharmaceuticals
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.34
Upside: +2,594.61%
Capricor Therapeutics
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $7.11
Upside: +321.94%
Mereo BioPharma Group
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.50
Upside: +180.00%
Disc Medicine
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $46.65
Upside: +182.96%
Zevra Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: $25
Current: $7.75
Upside: +222.58%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $20.45
Upside: +22.25%
Feb 26, 2025
Reiterates: Overweight
Price Target: $118
Current: $36.09
Upside: +226.96%
Feb 26, 2025
Reiterates: Neutral
Price Target: $36
Current: $32.15
Upside: +11.98%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $20.18
Upside: +232.01%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $6.22
Upside: +237.89%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $8.11
Upside: +257.58%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $2.85
Upside: +496.49%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $0.80
Upside: +901.38%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $13.15
Upside: +341.06%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.63
Upside: +318.25%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.60
Upside: +221.43%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $2.05
Upside: +582.93%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.32
Upside: +884.85%
Sep 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.68
Upside: -
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.55
Upside: +1,254.84%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.48
Upside: +1,151.56%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.59
Upside: +1,157.86%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.80
Upside: +721.43%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.13
Upside: +79,546.02%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.67
Upside: +5,989.41%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $2.79
Upside: +14,236.92%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.79
Upside: +10,640.46%
Feb 28, 2022
Initiates: Overweight
Price Target: $3,500
Current: $0.32
Upside: +1,100,528.93%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.65
Upside: +2,606.77%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.23
Upside: +3,558.54%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $0.70
Upside: +1,471.43%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.14
Upside: +5,163.16%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.13
Upside: +7,864.60%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.28
Upside: +196,775.00%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.54
Upside: +29,789.78%